Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
90.69 EUR | -0.66% | -1.21% | +1.04% |
12-12 | Gilead appoints Sanofi official Dietmar Berger as next chief medical officer | RE |
12-12 | Gilead Sciences Names Dietmar Berger as Chief Medical Officer | MT |
Capitalization | 114B 119B 106B 93.88B 169B 10,120B 187B 1,310B 486B 4,160B 448B 438B 18,152B | P/E ratio 2024 * |
16.6x | P/E ratio 2025 * | 12.1x |
---|---|---|---|---|---|
Enterprise value | 120B 126B 112B 99.38B 179B 10,713B 198B 1,387B 514B 4,404B 474B 464B 19,215B | EV / Sales 2024 * |
2.62x | EV / Sales 2025 * | 2.38x |
Free-Float |
87.09% | Yield 2024 * |
4.26% | Yield 2025 * | 4.47% |
Last Transcript: Sanofi
1 day | -0.66% | ||
1 week | -0.72% | ||
Current month | -1.52% | ||
1 month | -5.25% | ||
3 months | -13.27% | ||
6 months | +0.89% | ||
Current year | +1.04% |
Director | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 57 | 31/08/2019 |
Director of Finance/CFO | 62 | 31/03/2024 | |
Preethi Sundaram
CTO | Chief Tech/Sci/R&D Officer | 47 | - |
Manager | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 02/05/2013 | |
Patrick Kron
BRD | Director/Board Member | 71 | 30/04/2014 |
Director/Board Member | 59 | 29/04/2019 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.31% | 5 M€ | +4.56% | ||
3.66% | 128 M€ | +9.94% |
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-0.66% | -0.72% | +3.29% | +4.81% | 120B | ||
-1.72% | -5.24% | +33.79% | +220.45% | 717B | ||
-0.73% | +0.58% | +17.23% | +108.92% | 492B | ||
-0.27% | -2.19% | -5.69% | -11.63% | 353B | ||
-0.68% | -1.69% | +13.02% | +38.03% | 308B | ||
+1.50% | -2.22% | -2.98% | +39.42% | 252B | ||
-0.16% | +0.71% | +0.47% | -32.23% | 232B | ||
+0.28% | +0.84% | +4.68% | +28.99% | 208B | ||
+0.14% | -2.26% | +2.90% | +17.95% | 199B | ||
+0.24% | -0.10% | +0.03% | +29.95% | 147B | ||
Average | -0.04% | -1.37% | +6.67% | +44.47% | 302.86B | |
Weighted average by Cap. | -0.04% | -1.81% | +11.89% | +78.00% |
2024 * | 2025 * | |
---|---|---|
Net sales | 45.94B 48.19B 42.81B 37.94B 68.36B 4,090B 75.5B 529B 196B 1,681B 181B 177B 7,336B | 48.92B 51.31B 45.58B 40.4B 72.79B 4,355B 80.39B 564B 209B 1,790B 193B 188B 7,811B |
Net income | 6.94B 7.28B 6.46B 5.73B 10.32B 618B 11.4B 79.93B 29.63B 254B 27.34B 26.73B 1,108B | 9.83B 10.31B 9.16B 8.12B 14.63B 875B 16.16B 113B 42B 360B 38.76B 37.88B 1,570B |
Net Debt | 6.66B 6.98B 6.2B 5.5B 9.91B 593B 10.94B 76.72B 28.44B 244B 26.25B 25.65B 1,063B | 2.76B 2.89B 2.57B 2.28B 4.1B 245B 4.53B 31.76B 11.77B 101B 10.86B 10.62B 440B |
Date | Price | Change | Volume |
---|---|---|---|
12/12/24 | 90.69 € | -0.66% | 1,556,573 |
11/12/24 | 91.29 € | -0.50% | 1,246,198 |
10/12/24 | 91.75 € | -0.08% | 1,455,141 |
09/12/24 | 91.82 € | -0.39% | 1,250,170 |
06/12/24 | 92.18 € | +0.41% | 1,419,655 |
Real-time Euronext Paris, December 12, 2024 at 04:36 pm
More quotesQuarterly revenue - Rate of surprise
- Stock Market
- Equities
- SAN Stock
MarketScreener is also available in this country: United States.
Switch edition